Latest Breaking News On - வெப்பம் உயிரியல் - Page 10 : comparemela.com

by Frank Vinluan, NCBiotech writer December 21, 2020 . RESEARCH TRIANGLE PARK – Heat Biologics, a clinical-stage immunotherapies developer, is moving closer to human testing of a vaccine for COVID-19. The Morrisville-based biotech reported preclinical data showing that its vaccine candidate, ZVX-60, prompted the expression of two proteins key to an immune response. The Heat vaccine also led to the expression of the “spike protein” characteristic of the novel coronavirus. Heat develops drugs that activate T-cells and gets them to proliferate, mounting an immune response to disease. The company’s technology platform is the basis for drugs that employ gp96, a “heat shock” protein that activates a T-cell immune response. The company’s lead drug candidate, a cell therapy code-named HS-110, is currently in mid-stage testing as a treatment for non-small cell lung cancer.

United statesNorth carolinaUniversity of miamiJeff wolfBiotech centerCarolina biotechnology centerResearch triangle regionUniversity of miami miller school medicineHeat biologicsWest nileMiller schoolNorth carolina biotechnology centerResearch triangleLanding padஒன்றுபட்டது மாநிலங்களில்வடக்கு கரோலினா